University of Virginia Licensing & Ventures Group Seed Fund Announces Three Investments

Charlottesville, Virginia, January 17, 2018 – Since its launch, the UVA LVG Seed Fund has made three investments in companies based on technology developed from UVA research discoveries and licensed from the UVA Licensing & Ventures Group (LVG). Overseen by Bob Creeden, Managing Director of the Seed Fund & New Ventures at LVG, the Fund was created to propel UVA’s research enterprise and expand its capacity to drive innovation to the marketplace. The Fund encourages entrepreneurship and offers UVA-affiliated startups the capital to advance opportunities that are often considered too early for investment by traditional sources.

The second investment made in January 2017 helped TearSolutions, Inc. launch its next phase of clinical testing. Discovered by UVA Professor of Cell Biology and Ophthalmology Dr. Gordon Laurie, TearSolutions’ first-in-class therapy is a synthetic form of the protein lacritin which targets the causes of dry-eye disease.

“The Fund has made significant progress in its first year closing three deals with UVA startups that have emerged from varying schools and departments across Grounds,” says Bob Creeden. “We believe each company has potential to make an impact in the market which aligns with the UVA Cornerstone Plan to drive the local and regional economy.” Each new venture considered by the Fund undergoes an extensive due diligence process. Once the Fund makes each investment, Creeden and his team become actively engaged with each respective new venture offering resources and access to the broader UVA network, beginning with the committee members.

About UVA LVG Seed Fund

The University of Virginia created the $10 million UVA LVG Seed Fund with funding from the University and the UVA Health System to support new ventures emerging from the university portfolio. Operating as part of the UVA Licensing & Ventures Group (LVG), the main objectives of the fund are to support the UVA Cornerstone Plan, be capable of generating significant financial returns, and be diversified in supporting a broad range of innovation assets developed at UVA. The fund will reinvest its gains to provide capital for additional investments. It launched in 2016 and is governed by the Seed Fund Committee, comprised of five UVA alum who are all leaders in early-stage investing and startup development, which oversees each investment decision. The Managing Director of the Seed Fund & New Ventures Bob Creeden was appointed by LVG and the committee in September 2016.

About University of Virginia Licensing & Ventures Group

The Licensing & Ventures Group is the University of Virginia intellectual property management and innovation commercialization organization for UVA’s research portfolio (www.lvg.virginia.edu). Founded in 1977 as a 501(c)(3) UVA affiliated foundation, UVA LVG receives ~200 invention disclosures, executes ~80 commercial transactions, and launches 5-7 new companies each year. During the 2017 fiscal year, UVA LVG was awarded 82 patents in the US and abroad. Its mission is to maximize the impact of UVA innovation assets via commercialization while providing high levels of customer service, value-added business development, new venture creation, and a focus on driving quality transactions.

TearSolutions, Inc. Closes Series B Funding